What caused the IBXXF stock volume spike on 07 Mar 2026?

The spike was driven by event-led interest in Imagion’s clinical imaging programs and post-earnings attention. Volume hit **90,000** versus average **1**, creating an outsized relative volume. Thin liquidity on PNK amplified the price move.

What is Meyka AI’s forecast for IBXXF stock?

Meyka AI's forecast model projects a quarterly price of **$0.06** versus current **$0.015**, implying a **300.00%** upside. Forecasts are model-based projections and not guarantees.

Is IBXXF stock a buy based on today’s volume spike?

The Meyka grade is **B+** with a BUY suggestion, but fundamentals show negative EPS and weak liquidity. Treat the move as high-risk and size positions accordingly on PNK in the United States.

What are the key risks for IBXXF stock investors?

Key risks include thin trading liquidity, operating losses (EPS **-0.01**), high price-to-sales **183.28**, and potential dilution. Clinical trial outcomes and funding are primary execution risks.

US Stocks

90k volume spike: IBXXF Imagion Biosystems Ltd (PNK) 07 Mar 2026: Watch MagSense catalyst

ByDanny Kontos March 7, 2026March 7, 2026

IBXXF stock jumped 15.38% on a large intraday volume spike to 90,000 shares during market hours on 07 Mar 2026. The price moved to $0.015 from a prior close of $0.013, driven by renewed interest in Imagion Biosystems Limited’s clinical imaging programs. The spike stands out because average volume is listed at 1 share, producing a relative volume of 90,000.00, a clear trading anomaly that needs context. Traders should note this trade occurred on the PNK exchange in the United States and may reflect short-term event-driven flows rather than a sustained re-rating.